Scientific publications

Epigenetic Biomarkers for the Diagnosis and Treatment of Liver Disease

Mar 12, 2021 | Magazine: Cancers

María Arechederra 1 2, Miriam Recalde 1, María Gárate-Rascón 1, Maite G Fernández-Barrena 1 2 3, Matías A Ávila 1 2 3, Carmen Berasain 1 2 3


Research in the last decades has demonstrated the relevance of epigenetics in controlling gene expression to maintain cell homeostasis, and the important role played by epigenome alterations in disease development. Moreover, the reversibility of epigenetic marks can be harnessed as a therapeutic strategy, and epigenetic marks can be used as diagnosis biomarkers.

Epigenetic alterations in DNA methylation, histone post-translational modifications (PTMs), and non-coding RNA (ncRNA) expression have been associated with the process of hepatocarcinogenesis. Here, we summarize epigenetic alterations involved in the pathogenesis of chronic liver disease (CLD), particularly focusing on DNA methylation. We also discuss their utility as epigenetic biomarkers in liquid biopsy for the diagnosis and prognosis of hepatocellular carcinoma (HCC).

Finally, we discuss the potential of epigenetic therapeutic strategies for HCC treatment.

CITA DEL ARTÍCULO Cancers (Basel). 2021 Mar 12;13(6):1265. doi: 10.3390/cancers13061265.